Role of angiopoietin-2, endoglin, and placental growth factor in HIV-associated preeclampsia

References

• Suy A, Martinez E, Coll O, et al. Increased Risk of Pre-Eclampsia and Fetal Death in HIV-Infected Pregnant Women Receiving Highly Active Antiretroviral Therapy, Aids. 2006:20:59–66.
   PubMed Web of Science ®Google Scholar
• Wang A, Rana S, Karumanchi SA. Preeclampsia: The Role of Angiogenic Factors in its Pathogenesis, Physiology. 2009:24:147–158.
   PubMed Web of Science ®Google Scholar
• Holmes VA, Young I, Patterson CC, et al. The Role of Angiogenic and Antiangiogenic Factors in the Second Trimester in the Prediction of Preeclampsia in Pregnant Women With Type 1 Diabetes, Diabetes Care. 2013:36:3671–3677.
   PubMed Web of Science ®Google Scholar
• Kalumba VMS, Moodley J, Naidoo T. Is the Prevalence of Pre-Eclampsia Affected by HIV/AIDS? A Retrospective Case-Control Study: Cardiovascular Topics, Cardiovasc.J. Afr. 2013:24:24–27.
   PubMed Web of Science ®Google Scholar
• Escudero C, Roberts J, Myatt L, Feoktistov I. Impaired Adenosine-Mediated Angiogenesis in Preeclampsia: Potential Implications for Fetal Programming, Front. Pharmacol. 2014:5:1–13.
   Web of Science ®Google Scholar
• Minassian C, Thomas S, Williams DJ, et al. Acute Maternal Infection and Risk of Pre-Eclampsia: A Population-Based Case-Control Study, PLOS One. 2013:8:e73047. doi:10.1371/journal.pone.0073047.
   PubMed Web of Science ®Google Scholar
• Conde-Agudelo A, Villar J, Lindheimer M. Maternal Infection and Risk of Preeclampsia: Systematic Review and Meta Analysis, Am. J. Obstetrics Gynecol. 2008:198:7–22.
   Google Scholar
• Wimalasundera RC, Larbalestier N, Smith J. Pre-Eclampsia, Antiretroviral Therapy, and Immune Reconstitution, Lancet. 2002:360:1152–1154.
   Google Scholar
• Uzan, J. et al. Pre-Eclampsia: Pathophysiology, Diagnosis, and Management, Vasc. Health Risk Manag. 2011:7(7):467–474.
   PubMedGoogle Scholar
• Nicolaides KH, Bindra R, Turan OM, et al. A Novel Approach to First-Trimester Screening for Early Pre-Eclampsia Combining Serum PP-13 and Doppler Ultrasound, Ultrasound Obstet. Gynecol. 2006:27:13–17.
   Google Scholar
• Hirokoshi K, Maeshima Y, Kobayashi K, et al. Increase of Serum Angiopoietin-2 During Pregnancy Is Suppressed in Women With Preeclampsia, Am. J. Hypertens. 2005:18:1181–1188.
   Web of Science ®Google Scholar
• Naicker T, Khedun M, Moodley J, Pijnenborg R. Quantitative Analysis of Trophoblast Invasion in Preeclampsia, Acta Obstet. Gynecol. Scand. 2003:82:722–729.
   PubMed Web of Science ®Google Scholar
• Hasheesh NM, Waly M, Gouda M, Taweel NEL. Maternal Serum Soluble Endoglin in Patients with Pre-Eclampsia and Gestational Hypertension and its Relation to Doppler Study of the Fetomaternal Circulation, Med. J. Cairo. Univ. 2010:78:117–121.
   Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia, N. Engl. J. Med. 2006:355(10):992–1005.
   PubMed Web of Science ®Google Scholar
• De Vivo A, Baviera G, Giordano D, et al. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia, Acta Obstet. Gynecol. Scand. 2008:87:837–842.
   PubMed Web of Science ®Google Scholar
• Govender N, Naicker T, Moodley J. Maternal Imbalance Between Pro-Angiogenic and Anti-Angiogenic Factors in HIV-Infected Women with Pre-Eclampsia: Cardiovascular Topics, Cardiovasc. J. Afr. 2013:24(5):174–179.
   Google Scholar
• Ghosh SK, Raheja S, Tuli A, et al. Serum PLGF as a Potential Biomarker for Predicting the Onset of Preeclampsia, Arch. Gynecol. Obstet. 2012:285:417–422.
   Google Scholar
• Livingston JC, Chin R, Haddad B, et al. Reductions of Vascular Endothelial Growth Factor and Placental Growth Factor Concentrations in Severe Preeclampsia, Am. J. Obstet. Gynecol. 2000:183:1554–1557.
   Google Scholar
• Thadhani R, Mutter W, Wolf M, et al. First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia, J. Clin. Endocrinol. Metabolism. 2004:89:770–775.
   Google Scholar
• Hertig HA, Liere P. New markers in preeclampsia, Clinica Chimica Acta. 2010:411:1591–1595.
   PubMed Web of Science ®Google Scholar
• Molvarec A, Szarka A, Walentin S, et al. Circulating Angiogenic Factors Determined by Electrochemiluminescence Immunoassay in Relation to the Clinical Features and Laboratory Parameters in Women with Pre-Eclampsia, Hypertens. Res. 2010:33:892–898.
   Google Scholar
• Sarosh Rana SAK, Karumanchi SA, Levine RJ, et al. Sequential Changes in Antiangiogenic Factors in Early Pregnancy and Risk of Developing Preeclampsia, Hypertension. 2007:50:137–142.
   PubMed Web of Science ®Google Scholar
• Vatten LJ, Eskild A, Nilsen TIL, et al. Changes in Circulating Level of Angiogenic Factors from the First to Second Trimester as Predictors of Preeclampsia, Am. J. Obstet. Gynecol. 2007:196:239.e1–239.
   Google Scholar
• Moodley J. Potentially Increasing Rates of Hypertension in Women of Childbearing Age and During Pregnancy – be Prepared!, Cardiovasc. J. Africa. 2011:22:330–334.
   Web of Science ®Google Scholar
• Areechokchai D, Bowonwatanuwong C, Phonrat B, et al. Pregnancy Outcomes Among HIV-Infected Women Undergoing Antiretroviral Therapy, Open AIDS J. 2009:3:8–13.
   PubMedGoogle Scholar
• Gupta SK, Shen C, Moe SM, et al. Worsening Endothelial Function with Efavirenz Compared to Protease Inhibitors: A 12-Month Prospective Study, Plos ONE. 2012:7(9): e45716. doi:10.1371/journal.pone.0045716.
   Web of Science ®Google Scholar
• Machado ES, Krauss M, Megazzini K, et al. Hypertension, Preeclampsia and Eclampsia Among HIV-Infected Pregnant Women from Latin America and Caribbean Countries, J. Infect. 2014:68(6):572–580.
   Web of Science ®Google Scholar
• Ahmad SA. Elevated Placental Soluble Vascular Endothelial Growth Factor Receptor-1 Inhibits Angiogenesis in Preeclampsia, Circ. Res. 2004:95:884–891.
   Google Scholar
• Maynard SE, Crawford SL, Bathgate S, et al. Gestational Angiogenic Biomarker Patterns in High Risk Preeclampsia Groups, Am. J. Obstet. Gynecol. 2013:209(1):53.e1–9.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min J, Merchan J, et al. Excess Placental Soluble FMS-like Tyrosine Kinase 1 (sFlt1) may Contribute to Endothelial Dysfunction, Hypertension, and Proteinuria in Preeclampsia, J. Clin. Invest. 2003:111:649–658.
   Google Scholar
• Levine R. Circulating Angiogenic Factors and the Risk of Preeclampsia, N. Engl. J. Med. 2004:350:672–683.
   PubMed Web of Science ®Google Scholar
• McKeeman GC, Ardill J, Caldwell CM, et al. Soluble Vascular Endothelial Growth Factor Receptor-1(sFlt-1) is Increased Throughout Gestation in Patients who Have Preeclampsia Develop, Am. J. Obstet. Gynecol. 2004:191:1240–1246.
   Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating Angiogenic Factors and the Risk of Preeclampsia, N. Engl. J. Med. 2004:350:672–683.
   PubMed Web of Science ®Google Scholar